Terazosin

Terazosin
Clinical data
Trade names	Hytrin, Zayasel, others
AHFS/Drugs.com	Monograph
MedlinePlus	a693046
License data	US DailyMed: Terazosin;
Routes of; administration	By mouth
Drug class	α1 blocker
ATC code	G04CA03 (WHO) ;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Protein binding	90–94%
Elimination half-life	12 hours
Identifiers
	IUPAC name (RS)-6,7-Dimethoxy-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine;
CAS Number	63590-64-7 ;
PubChem CID	5401;
IUPHAR/BPS	7302;
DrugBank	DB01162 ;
ChemSpider	5208 ;
UNII	8L5014XET7;
KEGG	D08569 ;
ChEBI	CHEBI:9445 ;
ChEMBL	ChEMBL611 ;
CompTox Dashboard (EPA)	DTXSID3023639 ;
ECHA InfoCard	100.118.191
Chemical and physical data
Formula	C19H25N5O4
Molar mass	387.440 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(N3CCN(c2nc1cc(OC)c(OC)cc1c(n2)N)CC3)C4OCCC4;
	InChI InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22) ; Key:VCKUSRYTPJJLNI-UHFFFAOYSA-N ;
	(verify)

Terazosin, sold under the brand name Hytrin among others, is a medication used to treat symptoms of an enlarged prostate and high blood pressure. For high blood pressure, it is a less preferred option. It is taken by mouth.

Common side effects include dizziness, headache, feeling tired, swelling, nausea, and low blood pressure with standing. Severe side effects may include priapism and low blood pressure. Prostate cancer should be ruled out before starting treatment. It is an alpha-1 blocker and works by relaxing blood vessels and the opening of the bladder.

Terazosin was patented in 1975 and came into medical use in 1985. It is available as a generic medication. In 2021, it was the 234th most commonly prescribed medication in the United States, with more than 1 million prescriptions.